Before you make any knee-jerk reactions to Wall Street analyst notes, let's look at what has gone wrong for Iovance and how its situation could improve. In May, Iovance reported more than 40 treatment centers authorized to infuse patients with Amtagvi had enrolled more than 100 patients. Catanzaro downgraded the stock because more than four-fifths of enrolled patients at six treatment centers he surveyed still hadn't received a dose of Amtagvi by the end of June. A slow rollout of Amtagvi shouldn't have cau ...

No investor likes it when one of their stocks is hit with a recommendation downgrade from an analyst. That was the dynamic behind Iovance Biotherapeutics' (IOVA -2.16%) more than 2% decline in value on Monday. A onetime Iovance bull has considerably cooled on the stock, and this triggered a bit of a sell-off for the biotech. Biotech blues In his research note detailing the change, Catanzaro cited field research on the biotech's first commercialized drug, Amtagvi. He found that, "Despite a solid number of pa ...

SAN CARLOS, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its second quarter and first half 2024 financial results on Thursday, August 8, 2024. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET. To listen to the ...

SAN CARLOS, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its second quarter and first half 2024 financial results on Thursday, August 8, 2024. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET. To listen to the ...

Piper Sandler downgraded Iovance Biotherapeutics Inc IOVA, citing the slow launch of Amtagvi (lifileucel), a prescription medicine used to treat adults with a type of skin cancer that cannot be removed surgically or has spread to other parts of the body called unresectable or metastatic melanoma. Amtagvi is made from surgically removed tumor. Tumor-derived T cells are grown in a manufacturing center. Piper Sandler spoke with six authorized treatment centers (ATCs) to gauge the early utilization of Amtagvi. ...

Raising capital is a key concern for most businesses, but it's a particularly acute issue for biotechs approaching the commercialization of their first few products, and especially for those expecting to have substantial manufacturing expenses. Remember these two categories, as they're the groups that could soon pick up a new tailwind. As we all know, debt can have consequences, even if the tax shield is handy. If a biotech has no taxable income, there's nothing to offset the cost of interest payments. So u ...

Biotech stocks like Iovance Biotherapeutics (IOVA 3.44%) often look appealing because they could experience enormous growth in relatively short periods of time. Plus, over the long term, successful biotech companies have the opportunity to blossom into larger and larger versions, sometimes eventually joining the ranks of big pharmaceutical companies. And if a patient investor can get in on the ground level, it might just be possible to turn a small investment into millions. Here's what would need to happen ...

SAN CARLOS, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer, submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for lifileucel, a TIL cell therapy, for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a P ...

SAN CARLOS, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer, submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for lifileucel, a TIL cell therapy, for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a P ...

Earlier this year, share prices of Iovance Biotherapeutics (IOVA -1.23%) were soaring after one of its therapies obtained approval from regulators. Iovance stock would go on to reach share price highs of more than $18. Today, however, the stock trades at less than half that price. And in just three months, it has fallen by more than 40% as the hype surrounding the business appears to have evaporated. On Feb. 16, the Food and Drug Administration (FDA) granted accelerated approval for Iovance's cell therapy t ...